Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin Efficacy and Bone Safety in Older T2D Patients
NCT03386344Phase 3Terminated
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Feb 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03386344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386344.